UnitedHealthcare will require most colonoscopies to have prior authorization; the World Health Organization says that progress in reducing maternal and infant deaths has halted; hospitals are creating their own police forces to address increasing violence against staff.
Gastroenterologists learned in March that UnitedHealthcare plans to block many colonoscopies behind prior authorization starting on June 1, meaning that any United members seeking surveillance and diagnostic colonoscopies to detect cancer will need United’s approval first, or else have to pay out of pocket, reported STAT News. Doctors say that the prior authorization requirement will make it harder for patients to get endoscopic procedures, especially cancer diagnostic and surveillance procedures, done promptly. These procedures make up about 50% of those that gastroenterologists perform.
International progress on maternal and infant health is languishing, the World Health Organization (WHO) suggested in a report, according to The Washington Post. Agency officials mentioned “extraordinarily high” rates of preventable maternal deaths, stillbirths, and newborn deaths in a document released in May. Just in 2020, the agency reported that a combined 4.5 million deaths transpired among mothers and infants. To meet targets in areas including prenatal care, the presence of skilled health professionals at every birth, and postnatal care for newborns, the world would need to decrease maternal mortality by 11.6% annually this decade and continue reducing stillbirths and infant deaths.
This May, Georgia Governor Brian Kemp, a Republican, signed a law that increases criminal penalties for assaults against hospital workers and permits health care facilities in the state to make independent police forces, reported NPR. The law comes in response to a testimony of hospital violence, hospital lobbying, and data documenting an increase in violence against health care workers. In appointing the law, Georgia joined other states trying to reverse a rise in violence over the last few years through more rigid criminal penalties and boosted law enforcement.
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
2 Commerce Drive
Cranbury, NJ 08512